Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients With Relapsed or Refractory Advanced Solid Tumors

NCT06014502 is registered in ClinicalTrials.gov with ImmunoGenesis as lead sponsor.

NCT NCT06014502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06014502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients With Relapsed or Refractory Advanced Solid Tumors
Lead sponsor
ImmunoGenesis
Phase
Phase 1
Overall status
Recruiting
Start date
September 7, 2023
Completion date
December 31, 2028
Enrollment
105 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor